Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 20:13:1259784.
doi: 10.3389/fonc.2023.1259784. eCollection 2023.

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Keqiang Li #  1   2 , Guoqing Xie #  1   2 , Xiyue Deng  1   2 , Yu Zhang  1   2 , Zhankui Jia  1 , Zhenlin Huang  1
Affiliations
Review

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Keqiang Li et al. Front Oncol. .

Abstract

Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic chemotherapeutic payloads. This review highlights recent advancements, opportunities, and challenges in ADC application for urinary tumors. We discuss the FDA-approved ADCs and other novel ADCs under investigation, emphasizing their potential to improve patient outcomes. Furthermore, we explore strategies to address challenges, such as toxicity management, predictive biomarker identification, and resistance mechanisms. Additionally, we examine the integration of ADCs with other treatment modalities, including immune checkpoint inhibitors, targeted therapies, and radiation therapy. By addressing these challenges and exploring innovative approaches, the development of ADCs may significantly enhance therapeutic options and outcomes for patients with advanced urinary tumor.

Keywords: ADC; bladder; kidney; prostate; urinary tumors; urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The core components and mechanism of antibody–drug conjugates (ADCs).
See this image and copyright information in PMC

References

    1. Sun JX, Xu JZ, Liu CQ, An Y, Xu MY, Zhong XY, et al. . The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample Mendelian randomization. J Med Virol (2023) 95(1):e28208. doi: 10.1002/jmv.28208 - DOI - PMC - PubMed
    1. Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, et al. . Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Mil Med Res (2021) 8(1):60. doi: 10.1186/s40779-021-00354-z - DOI - PMC - PubMed
    1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. JAMA (2019) 322(13):1294–304. doi: 10.1001/jama.2019.14745 - DOI - PMC - PubMed
    1. Netto GJ, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, et al. . The 2022 world health organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol (2022) 82(5):469–82. doi: 10.1016/j.eururo.2022.07.002 - DOI - PubMed
    1. Cathomas R, Lorch A, Bruins HM, Comperat EM, Cowan NC, Efstathiou JA, et al. . The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol (2022) 81(1):95–103. doi: 10.1016/j.eururo.2021.09.026 - DOI - PubMed

LinkOut - more resources